On Saturday, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) released new Phase 3 PEGASUS study results on Saturday. The data show that its therapy Palynziq (pegvaliase-pqpz) significantly reduced blood ...

Hi, good morning, everybody. I'm Kristen Kluska, one of the biotech analysts at Cantor. Very happy to be hosting PTC Therapeutics this morning. We have Dr. Matt Klein, CEO; and Pierre Gravier, the CFO ...

PTC's annual run-rate growth supports super growth in cash flow for investors. The company's growth is even more impressive, considering the weak manufacturing environment over the last couple of ...

Rabindra Narayan, widely hailed as the Father of Punjabi Satellite Television, has officially stepped down from his role as President and Managing Director of PTC Network. After nearly two decades at ...

The FDA rejected PTC Therapeutics' NDA for vatiquinone, citing insufficient efficacy evidence and requiring an additional study for resubmission. The MOVE-FA trial, a Phase II/III study, failed to ...

The U.S. Food and Drug Administration has turned away PTC Therapeutics' proposed vatiquinone treatment for the rare, inherited neurodegenerative disorder Friedreich's ataxia over concerns about the ...

ISLAMABAD: The Pakistan Textile Council (PTC) has proposed that the government engage a team of industry experts before initiating talks on a Preferential Trade Agreement (PTA) with the United States.

"Today's most advanced products—from AI hardware to industrial machinery—are more complex, integrated, and engineering-intensive than ever before," said Neil Barua, President and CEO, PTC. "By ...

BOSTON, July 30, 2025 /PRNewswire/ -- PTC (NASDAQ: PTC) today announced that it is expanding the scope of its collaboration with NVIDIA, the world leader in accelerated computing. PTC is integrating ...

Shares of PTC Therapeutics climbed after the company said federal regulators approved its treatment for elevated levels of a certain amino acid in the blood. The stock was up 11%, at $49.08, midday ...

PTC Therapeutics, Inc. (NASDAQ:PTCT) announced it has gained FDA approval for SEPHIENCE on Monday. “We are excited to have reached this important milestone for those affected by PKU,” said Matthew B.